Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these two medicines is off the table, and how to choose between them
Why would anyone consider taking tirzepatide and semaglutide at the same time?
It's a fair question, and if you're asking it, you're probably frustrated. Maybe Wegovy has worked only partially, or you've heard that Mounjaro tends to produce greater average weight loss in trials and you're wondering whether adding it on top could close the gap faster. That logic is understandable. It's also why it's worth being clear about why it doesn't hold up clinically.
Mounjaro (tirzepatide) activates both the GIP and GLP-1 receptors. Wegovy (semaglutide) targets the GLP-1 receptor alone. When you take tirzepatide, the GLP-1 pathway is already engaged, and if you're still wondering whether you can use Mounjaro and Wegovy together, adding a separate GLP-1 agonist alongside it would be redundant at best. At worst, the combined GI side-effect load (nausea, vomiting, delayed gastric emptying) could be significantly harder to tolerate, and there is no trial evidence that the combination produces better outcomes than either medicine at its therapeutic dose. You can find a fuller clinical discussion of taking tirzepatide and semaglutide together if you want the mechanism in more detail.
No licensed guideline, NICE appraisal or NHS protocol supports dual GLP-1 therapy for weight management. A prescriber reviewing your case simply would not approve both.
So what does the evidence actually say about each medicine separately?
If the underlying question is about effectiveness, the trial data is genuinely useful. In the SURMOUNT-1 study (involving around 2,500 adults with obesity) tirzepatide at the highest dose produced an average weight reduction of roughly 20–21% over 72 weeks, cited in the NEJM's SURMOUNT-1 publication. Wegovy at the standard 2.4mg maintenance dose achieved around 15% average reduction over 68 weeks in the STEP 1 trial. The gap narrowed in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, though tirzepatide still showed greater average loss.
The newer 7.2mg Wegovy dose, approved by the MHRA in January 2026 as a maintenance option and then as a dedicated single-dose pen in April 2026, reported around 20.7% average weight loss over 72 weeks, bringing results closer to the highest tirzepatide dose. Dose availability is confirmed at consultation rather than assumed.
| Factor | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Average weight loss (trial data) | ~20–21% at 15mg over 72 weeks (SURMOUNT-1, NEJM) | ~15% at 2.4mg over 68 weeks (STEP 1, NEJM); ~20.7% at 7.2mg over 72 weeks (MHRA, 2026) |
| UK licence (weight management) | BMI ≥30, or ≥27 with a weight-related condition | BMI ≥30, or ≥27 with a weight-related condition |
| NICE recommendation | TA1026 (Dec 2024, updated Sep 2025) | TA875 (Mar 2023), max 2 years, specialist service |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
Both medicines are Black Triangle (▼) products subject to additional MHRA monitoring. Side-effect profiles overlap considerably, with nausea, changes in bowel habit and fatigue the most commonly reported, full detail sits in the NHS medicines page for tirzepatide and the equivalent for semaglutide.
Can you switch from one to the other, or take one after finishing the other?
Switching is different from combining. If a prescriber decides semaglutide isn't producing sufficient results, moving to tirzepatide is a clinical option, and vice versa. The question of whether Mounjaro works after Wegovy is one our prescribers consider on a case-by-case basis, factoring in dose history, response and tolerability. There's also the separate question of whether Wegovy is worth trying if Mounjaro hasn't delivered expected results.
Switching isn't a same-day decision. Wash-out periods, current dose, and the reason for switching all feed into the clinical assessment. A prescriber who has your full history is the right person to make that call. What isn't on the table is running both medicines concurrently.
What's the right next step if you're unsure which medicine fits your situation?
The honest answer is that neither a forum nor a search result can tell you. Weight, health history, any existing conditions, medicines you already take, and how your body responded to any previous treatment all shape the decision. Our clinical team (you can read more about our prescribers on the clinical team page) reviews each consultation personally. The cost comparison between Mounjaro and Wegovy is worth understanding too, since private treatment pricing varies by dose and provider.
Which medicine suits you is a clinical decision made with our prescribers, not a choice to make based on trial averages alone. The free consultation is where that conversation starts. Check eligibility and start your free consultation, a real clinician reviews your answers the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.